RS/IST-ID

Development and preclinical evaluation of radiopharmaceuticals with several radionuclides

Biomedical services

The RS/IST-ID facilities are located in the Technological and Nuclear Campus of Instituto Superior Técnico, Universidade Lisboa near Lisbon. These facilities are licensed for handling a wide range of radionuclides relevant for the design, development and preclinical evaluation of radiolabeled molecules and nanoparticles for Molecular Imaging (PET and SPECT), Targeted Radionuclide Therapy and Theranostic applications.

A multidisciplinary team of researchers can support the main steps of the development and preclinical evaluation of radiopharmaceuticals through the access to the following dedicated facilities (https://c2tn.tecnico.ulisboa.pt/facilities):

  • Laboratories for Radiosynthesis (hot cells, glove boxes and fume hoods for the safe handling of various radionuclides).
  • Laboratories for Cellular Studies (fully equipped for cell culture, shielded fume cupboard and shielded biohazard cabinet dedicated for cell studies of radiolabelled compounds).
  • Laboratory for Animal Studies approved by the National Authority for small rodents’ experimentation. Animal housing facility with individual ventilated cage system; laminar flow cabinet, shielded fume hoods for animal handling and injection of radioactive compounds.
Bobadela, Portugal

Experiments available

Development of radiolabelling strategies for different classes of molecules (e.g., peptides or antibodies and their fragments) using different radionuclides for diagnosis and therapy, comprising the synthesis and characterization of cold precursors and surrogates, bioconjugation and purification of radioconjugates
Preclinical evaluation of radioconjugates
Radiochemical characterization and in vitro stability studies
Cell (2D and 3D cultures) studies (receptor binding affinity, uptake, subcellular localization, radiobiological assays)
Animal studies in different strains of normal mice and immunodeficient mice models (biodistribution, pharmacokinetics, in vivo stability and radionuclide therapeutic efficacy assays)